Skip to main content
OpenTrials

Clinical trial condition

Unresectable Malignant Solid Neoplasm

Explore clinical trials studying Unresectable Malignant Solid Neoplasm. Study availability and eligibility vary by location and protocol.

37 public trials 14 recruiting studies
Refine in advanced search Browse all conditions

Unresectable Malignant Solid Neoplasm trial results

Active, Not Recruiting

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

NCT03872427

Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor, +6 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
View all 31 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Conditions
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, +80 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
View all 23 locations
View Trial Details
Active, Not Recruiting

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

NCT02862275

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematopoietic and Lymphoid Cell Neoplasm, +9 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Moffitt Cancer Center-International Plaza Tampa, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Emory University Hospital Midtown Atlanta, Georgia, United States
View Trial Details
Active, Not Recruiting

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

NCT03842228

Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, +5 more
Locations
  • Keck Medicine of USC Buena Park Buena Park, California, United States
  • Keck Medicine of USC Koreatown Los Angeles, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

NCT04317105

Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, +5 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Texas at Austin Austin, Texas, United States
  • University of Texas Medical Branch Galveston, Texas, United States
  • UT MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, Not Recruiting

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

NCT03502733

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +12 more
Locations
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • UT MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, Not Recruiting

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

NCT04068194

Conditions
Adenocarcinoma, Biliary Tract Diseases, Biliary Tract Neoplasms, +24 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
View all 46 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

NCT04514497

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +38 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Yale University New Haven, Connecticut, United States
  • Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut, United States
View all 23 locations
View Trial Details

Related conditions